CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 213-222

  Giessmann, Thomas ^b   Modess, Christiane ^b   Hecker, Ute ^b   Zschiesche, Michael ^b   Dazert, Peter ^b   Kunert Keil, Christiane ^b   Warzok, Rolf ^b   Engel, Georg ^b   Weitschies, Werner ^b   Cascorbi, Ingolf ^b   Kroemer, Heyo K ^b   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; RIFAMPICIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSPORT; ENANTIOMER; ENZYME DEFICIENCY; FECES; GENE INDUCTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STEADY STATE; UPREGULATION;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CARBAZOLES; CYTOCHROME P-450 CYP2D6; DUODENUM; FEMALE; GENOTYPE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; METABOLIC CLEARANCE RATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROPANOLAMINES; RIFAMPIN; STATISTICS, NONPARAMETRIC; VARIATION (GENETICS);

EID: 12144286498     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.10.004     Document Type: Article

References (30)

1. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
2. Packer M., Briston M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
3. Messerli F.H. Implications of discontinuation of doxazosin arm of ALLHAT. Lancet. 355:2000;863-864.
4. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 26:1994;335-346.
5. Oldham H.G., Clarke S.E. In vitro identification of the cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 25:1997;970-977.
6. Zhou H.H., Wood A.J.J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther. 57:1995;518-524.
7. Graff D.W., Williamson K.M., Pieper J.A., Carson S.W., Adams K.F., Cascio W.E., et al. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol. 41:2001;97-106.
8. Neuhoff S., Langguth P., Dressler C., Andersson T.B., Regardh C.G., Spahn-Langguth H. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 38:2000;168-179.
9. de Mey C., Brendel E., Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol. 29:1990;486-490.
10. Jonsson O., Behnam-Motlagh P., Persson M., Henriksson R., Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 58:1999;1801-1806.
11. Kaijser M., Johnsson C., Zezina L., Backman U., Dimeny E., Fellstrom B. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant. 11:1997;577-581.
12. Zschiesche M., Lemma G.L., Klebingat K.J., Franke G., Terhaag B., Hoffmann A., et al. Stereoselective disposition of talinolol in man. J Pharm Sci. 91:2002;303-311.
13. Moore J.T., Kliewer S.A. Use of the nuclear receptor PXR to predict drug interactions. Toxicology. 153:2000;1-10.
14. Rae J.M., Johnson M.D., Lippman M.E., Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 299:2001;849-857.
15. Geick A., Eichelbaum M., Burk O. Nuclear response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 276:2001;14581-14587.
16. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 25:2002;2908-2915.
17. Hokama N., Hobara N., Kameya H., Ohshiro S., Sakanashi M. Rapid and simple micro-determination of carvedilol in rat plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 732:1999;233-238.
18. Eisenberg E.J., Patterson W.R., Kahn G.C. High-performance liquid chromatographic method for the simultaneous determination of the enantiomers of carvedilol and its O-desmethyl metabolite in human plasma after chiral derivatization. J Chromatogr. 493:1989;105-115.
19. Niemi M., Cascorbi I., Timm R., Kroemer H.K., Neuvonen P.J., Kivisto K.T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 72:2002;326-332.
20. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population allele frequencies and phenotypic consequences. Am J Hum Genet. 60:1997;284-295.
21. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 69:2001;169-174.
22. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 72:2002;572-583.
23. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 104:1999;147-153.
24. Fromm M.F., Kauffmann H.M., Fritz P., Burk O., Kroemer H.K., Warzok R.W., et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 157:2000;1575-1580.
25. Wuttke H., Rau T., Heide R., Bergmann K., Bohm M., Weil J., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther. 72:2002;429-437.
26. Evans W.E., McLeod H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 348:2003;538-549.
27. Nolte K., Backfisch G., Neidlein R. In vitro absorption studies with carvedilol using a new model with porcine intestine called BM-RIMO (Boehringer-Mannheim ring model). Arzneimittelforschung. 49:1999;745-749.
28. Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A in vitro-in vivo correlation. Br J Pharmacol. 118:1996;1841-1847.
29. Gerk P.M., Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther. 302:2002;407-415.
30. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings a new type of drug/drug interaction. Clin Pharmacol Ther. 68:2000;345-355.